VEGENICS LIMITED

Patent Applications and Registrations

Patent applications and USPTO patent grants for VEGENICS LIMITED.The latest application filed is for "flt4 (vegfr-3) as a target for tumor imaging and anti-tumor therapy".

Company Profile

0.19.17

VEGENICS LIMITED - TOORAK AU
Vegenics Limited - Toorak Victoria AU
Vegenics Ltd. - Toorak Victoria AU
Vegenics Limited - Victoria AU

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Flt4 (vegfr-3) As A Target For Tumor Imaging And Anti-tumor Therapy App 20150141622 - ALITALO; KARI ; et al.	2015-05-21
Autologous Lymph Node Transfer In Combination With Vegf-c Or Vegf-d Growth Factor Therapy To Treat Secondary Lymphedema And To Improve Reconstructive Surgery App 20120125348 - ALITALO; KARI ; et al.	2012-05-24
Expression Vectors and Cell Lines Expressing Vascular Endothelial Growth Factor D, and Method of Treating Melanomas App 20110269146 - Achen; Marc G. ; et al.	2011-11-03
Growth Factor Binding Constructs Materials and Methods App 20110243912 - Alitalo; Kari ; et al.	2011-10-06
Chimeric Anti-VEGF-D Antibodies and Humanized Anti-VEGF-D Antibodies and Methods of Using the Same App 20110189170 - ACHEN; MARC GREGORY ; et al.	2011-08-04
Treatment Of Pulmonary Edema App 20110142839 - Achen; Marc G. ; et al.	2011-06-16
Expression vectors and cell lines expressing vascular endothelial growth factor D Grant 7,947,472 - Achen , et al. May 24, 2	2011-05-24
Expression Vectors And Cell Lines Expressing Vascular Endothelial Growth Factor D, And Method Of Treating Melanomas App 20110059890 - ACHEN; MARC G. ; et al.	2011-03-10
Methods for inhibiting VEGF-D Grant 7,887,800 - McColl , et al. February 15, 2	2011-02-15
Mammalian cells that express VEGF-D polypeptides Grant 7,871,798 - Achen , et al. January 18, 2	2011-01-18
Growth factor binding constructs materials and methods Grant 7,855,178 - Alitalo , et al. December 21, 2	2010-12-21
Chimeric anti-VEGF-D antibodies and humanized anti-VEGF-D antibodies and methods of using same Grant 7,846,437 - Achen , et al. December 7, 2	2010-12-07
Method of treating lymphedema comprising administering VEGF-D Grant 7,829,536 - Ferrell , et al. November 9, 2	2010-11-09
Therapy targeting FLT4 (VEGER-3) expressed in blood vessels Grant 7,829,091 - Alitalo November 9, 2	2010-11-09
Methods of using antibodies to VEGF-C Grant 7,794,756 - Alitalo , et al. September 14, 2	2010-09-14
Antibody diagnostic kits and methods of use Grant 7,785,803 - Achen , et al. August 31, 2	2010-08-31
Vascular endothelial growth factor C (VEGF-C) protein and gene, mutants thereof, and uses thereof Grant 7,727,761 - Alitalo , et al. June 1, 2	2010-06-01
Vascular endothelial growth factor C (VEGF-C) protein diagnostic Grant 7,709,270 - Alitalo , et al. May 4, 2	2010-05-04
Use of VEGF-C or VEGF-D in Reconstructive Surgery App 20100041605 - Alitalo; Kari ; et al.	2010-02-18
Vascular endothelial growth factor D (VEGF-D) polypeptides and methods of use Grant 7,662,932 - Achen , et al. February 16, 2	2010-02-16
Materials and Methods Involving Hybrid Vascular Endothelial Growth Factor DNAs and Proteins App 20090318352 - Alitalo; Kari ; et al.	2009-12-24
VEGFR-3 inhibitor materials and methods Grant 7,611,711 - Alitalo , et al. November 3, 2	2009-11-03
Growth Factor Binding Constructs Materials and Methods App 20090155268 - Alitalo; Kari ; et al.	2009-06-18
Chimeric Anti-vegf-d Antibodies And Humanized Anti-vegf-d Antibodies And Methods Of Using Same App 20090155252 - Achen; Marc Gregory ; et al.	2009-06-18
Methods for treating neoplastic disease characterized by vascular endothelial growth factor D expression, for screening for neoplastic disease or metastatic risk, and for maintaining vascularization of tissue Grant 7,534,572 - Achen , et al. May 19, 2	2009-05-19
VEGF-D polynucleotides and methods of use App 20090087905 - Achen; Marc G. ; et al.	2009-04-02
Methods and compositions for activating VEGF-D and VEGF-C Grant 7,479,270 - McColl , et al. January 20, 2	2009-01-20
Modulation Of Vegf-c/vegfr-3 Interactions In The Treatment Of Rheumatoid Arthritis App 20090017011 - Alitalo; Kari ; et al.	2009-01-15
Lymphatic Endothelial Cells Materials And Methods App 20080317723 - Alitalo; Kari ; et al.	2008-12-25
Growth Factor Antagonists For Organ Transplant Alloimmunity And Arteriosclerosis App 20080267956 - Alitalo; Kari ; et al.	2008-10-30
Autologous Lymph Node Transfer In Combination With Vegf-c Or Vegf-d Growth Factor Therapy To Treat Secondary Lymphedema And To Improve Reconstructive Surgery App 20080267924 - Alitalo; Kari ; et al.	2008-10-30
VEGFR-3 fusion proteins Grant 7,422,741 - Alitalo , et al. September 9, 2	2008-09-09
Antibodies to VEGF-C Grant 7,423,125 - Alitalo , et al. September 9, 2	2008-09-09
Soluble neuropilin/growth factor receptor fusion proteins Grant 7,420,042 - Alitalo , et al. September 2, 2	2008-09-02
Vascular endothelial growth factor D(VEGF-D) antibodies and methods of use Grant 7,410,639 - Achen , et al. August 12, 2	2008-08-12
Vascular Endothelial Growth Factor D(vegf-d) Antibodies And Vectors, And Methods Of Uses App 20080070831 - ACHEN; MARC G. ; et al.	2008-03-20

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.